Silo Pharma, Inc. - Common Stock (SILO)

Competitors to Silo Pharma, Inc. - Common Stock (SILO)

ATMA Journey Centers

ATMA Journey Centers provides psychedelic-assisted therapy sessions and focuses primarily on the therapeutic application of psychedelics in a clinical setting. They compete with Silo Pharma by offering direct treatment options, which can appeal to patients and healthcare providers looking for immediate solutions for mental health issues. While ATMA does not focus on drug development in the same sense as Silo, its hands-on approach in providing services may give it an edge in capturing the therapeutic market.

COMPASS Pathways 

COMPASS Pathways is a mental health care company focused on developing psilocybin therapy for treatment-resistant depression. They have a well-documented clinical research progression and have gained significant visibility and support from both the investment community and regulatory bodies. While Silo Pharma explores similar avenues, COMPASS's clinical trial results and established relationships within the psychedelic research community give it a competitive advantage in securing investment and public interest.

Cybin

Cybin is an emerging biotechnology company taking a novel approach to psychedelic-based therapies for mental health disorders. Each company is utilizing psychedelics in their research and drug development; however, Cybin’s innovative technologies and strong focus on developing proprietary formulations are central to its strategy. This focus allows Cybin to potentially enhance efficacy and safety profiles of its treatments, offering a competitive edge over Silo Pharma in advancing drug development more efficiently.

Field Trip Health

Field Trip Health operates both as a psychedelic-focused biotechnology company and a provider of psychedelic-assisted therapies. They have established clinics and research operations that make them uniquely positioned in the market. While Silo Pharma is more focused on the development of pharmaceutical products, Field Trip's dual approach allows it to capitalize on immediate market needs while also pursuing drug development, granting it a broader market presence and competitive advantage.

MindMed 

MindMed focuses on developing psychedelic-inspired medicines for treating mental health disorders and addiction. Similar to Silo Pharma, MindMed is targeting the emerging market for psychedelic therapies, especially in the context of FDA-approved clinical trials. MindMed has attracted attention for its aggressive development pipeline and partnerships, which may provide it with a competitive edge in terms of funding and resources, allowing for faster progression through the clinical development stages.